Table 1 Characteristics of the study population
From: Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors
Overall | |
|---|---|
(N = 62) | |
Gender | |
Female | 41 (66.1%) |
Male | 20 (32.3%) |
Missing | 1 (1.6%) |
Race | |
White | 48 (77.4%) |
Black | 12 (19.4%) |
Other | 1 (1.6%) |
Missing | 1 (1.6%) |
Cancer Type | |
Breast | 23 (37.1%) |
Lymphoma | 33 (53.2%) |
Sarcoma | 6 (9.7%) |
Coronary Artery Disease | |
No | 58 (93.5%) |
Yes | 4 (6.5%) |
Smoking History | |
No | 42 (67.7%) |
Yes | 20 (32.3%) |
Diabetes | |
No | 52 (83.9%) |
Yes | 10 (16.1%) |
Hypertension | |
No | 40 (64.5%) |
Yes | 22 (35.5%) |
Anthracycline | |
No | 20 (32.3%) |
Yes | 42 (67.7%) |
Diuretic | |
No | 50 (80.6%) |
Yes | 12 (19.4%) |
Beta Blocker | |
No | 58 (93.5%) |
Yes | 4 (6.5%) |
ACE Inhibitor | |
No | 53 (85.5%) |
Yes | 9 (14.5%) |
Angiotensin Receptor Blocker | |
No | 58 (93.5%) |
Yes | 4 (6.5%) |
Calcium Channel Blocker | |
No | 57 (91.9%) |
Yes | 5 (8.1%) |
Lipid Lowering Drugs | |
No | 42 (67.7%) |
Yes | 20 (32.3%) |
Baseline IMF, cm2 | |
Mean (SD) | 9.13 (4.08) |
Baseline BMI, kg/m2 | |
Mean (SD) | 30.0 (5.76) |
Change in EF from Baseline, % | |
Mean (SD) | −5.12 (8.25) |
Baseline Systolic BP, mmHg | |
Mean (SD) | 119 (17.5) |
Baseline Diastolic BP, mmHg | |
Mean (SD) | 69.8 (13.5) |